Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 13,800 shares at $15.00 ($207K) on 2023-11-22, disclosed to the SEC on 2023-11-27.
Scheduled sale ($207k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |
| AVTE | SELL | 2023-06-07 | $37K | — | Filing → |